Radyus Research Partners with Eurofins CDMO Alphora to Streamline Biotech R&D

• Radyus Research and Eurofins CDMO Alphora have entered a strategic partnership to support early-stage drug development for biotech companies.

• The collaboration integrates preclinical and manufacturing capabilities into a unified, end-to-end solution.

Radyus Research and Eurofins CDMO Alphora have announced a strategic partnership aimed at streamlining early-stage drug development for biotech clients globally. The collaboration brings together Radyus’s development and regulatory expertise with Alphora’s process development and GMP manufacturing capabilities.

Based in the U.S., Radyus Research will provide strategic input across drug development planning, efficacy and safety studies, regulatory operations, and clinical trial execution. Eurofins CDMO Alphora, headquartered in Canada, will support the alliance with its experience in manufacturing small molecule APIs, biologics, and drug products.

The companies aim to reduce inefficiencies in the development process by integrating services from preclinical through to clinical proof-of-concept. This model is designed to improve execution, minimise handoffs, and enhance program success rates for clients.

“We’re excited to launch this partnership and unlock the value for our clients,” said Marta New, CEO of Radyus Research. “It reflects our joint belief that long-term collaboration, rather than transactional engagement, is the key to efficient drug development.”

According to both firms, the new alliance is intended to reflect the collaborative and global nature of modern biopharmaceutical development. The partnership will offer biotech clients a unified services platform with a long-term focus on delivery and operational excellence.